Acute angle closure glaucoma following the use of intranasal cocaine during dacryocystorhinostomy

Many thousands of dacryocystorhinostomies (DCRs) are performed by ophthalmologists routinely without problems. Postoperative pain and nausea may wrongly be attributed to wound pain and post-anaesthetic nausea. Medical and nursing staff need to be aware of the potential for intraocular cocaine to precipitate acute angle closure glaucoma (AACG). We report two cases of AACG following the use of intranasal cocaine and subcutaneous lignocaine (lidocaine) with adrenaline during DCR surgery. We believe this to be the second report of such cases.

Case report

Two women, a 67 year old and a 75 year old, developed right sided AACG immediately after ipsilateral DCR surgery. Both patients were treated successfully for AACG. Cocaine is a known mydriatic and can induce angle closure glaucoma in predisposed individuals. Adrenaline in the local anaesthetic solution and intravenous atropine sometimes used during general anaesthesia are also known mydriatics.

We performed right sided external DCR surgery under general anaesthesia on both females. Regional preparation included a cocaine nasal pack (5% solution) and infiltration with lignocaine and adrenaline 1:200 000 at the proposed incision site subcutaneously. Preoperative intraocular pressures were within normal limits and there was no history of previous attacks of AACG or subacute angle closure glaucoma in either patient. Overnight, both developed right eye pain and nausea and each was given analgesia and an antiemetic. Medical staff were not called to review the patients. The following morning, dressings were removed and a diagnosis of right sided AACG was made. Each patient had corneal oedema, a mid-dilated and non-reactive pupil, anterior chamber flare, and 360 degrees of angle closure on gonioscopy.

In the 67 year old, the intraocular pressure measured 18 mm Hg in the right eye. This may be explained by spontaneous termination of the attack as a result of ciliary body ischaemia and suppression of aqueous secretion secondary to a high intraocular pressure overnight. In the left eye the intraocular pressure was 15 mm Hg and gonioscopy revealed 270 degrees of grade I open angle, and 90 degrees of complete angle closure. Uneventful bilateral YAG iridotomy was performed.

In the 75 year old, the pressure was recorded as 57 mm Hg in the right eye and only dropped to 39 after two doses of intravenous mannitol. Gonioscopy of the left eye revealed a 360 degree closable angle, grade 0-1. Uneventful bilateral YAG iridotomy was performed. The corneal oedema resolved over the following week in both patients and visual field testing revealed no glaucomatous defect. Both patients require ongoing antiglaucoma therapy.

Comment

Cocaine is the only local anaesthetic to block noradrenaline neurotransmission at the presynaptic adrenergic receptors. This agent provides anaesthesia and haemostasis, making the use of cocaine desirable in lacrimal drainage surgery. Its use in DCR surgery was first described by Dupuy-Dutemps and Bourgener in 1922. We have routinely used cocaine for our DCR surgery, and emphasise the need to remain cognisant of its possible local and systemic side effects.

Cocaine is well absorbed from mucosal surfaces, reaching plasma levels similar to those achieved with intravenous administration. In adults, 50–95 mg is a psychoactive dose. The maximum allowable dose is 3 mg/kg; 1 g or 10 ml of a 10% solution represents a fatal dose for an adult. Usually, 80–200 mg of cocaine is administered intranasally in DCR surgery. Systemic cocaine toxicity has been reported in patients undergoing DCR surgery under general anaesthesia.

AACG was described in the early 20th century with the use of cocaine as a corneal mydriatic. More recently, a case of AACG associated with ipsilateral intranasal cocaine abuse was reported. In 1999, Hari et al described a single case of AACG following the use of cocaine in DCR surgery. Our two case reports strongly suggest that the use of intranasal cocaine to aid DCR surgery may precipitate AACG.

It is highly probable that the mydriasis which precipitated the attack of AACG was caused by the intranasal cocaine rather than the low concentration of subcutaneous adrenaline (1:200 000). There are two possible mechanisms of cocaine entry into the eye during DCR. Inadvertent transfer of cocaine from the surgeon’s glove to the patient’s conjunctival sac is possible if fresh gloves are not used between cocaine nasal packing and the infiltration of local anaesthetic. Alternatively, residual cocaine in the nasal cavity has direct access to the conjunctival sac after the lacrimal sac anastomosis in the DCR procedure.

Other potential causes of AACG include the mydriatic effect of the adrenaline in the lignocaine 1%, 1:200 000 adrenaline, and atropine given intravenously during general anaesthesia.

At this concentration, subcutaneously administered adrenaline is unlikely to have precipitated the acute angle closure glaucoma. Atropine was not used during anaesthesia in either patient.

Given the apparent rarity of this proposed event, we cannot definitively conclude that lacrimal surgeons should change their approach to patients undergoing DCR surgery. However, it is important to remain cognisant of this potential complication and educate both nursing staff and medical trainees in ophthalmology and otolaryngology as to this potential complication. In addition, it would be reasonable to pad only the wound and not occlude the eye, which may have allowed the origin of the pain in our cases to be more readily identified. Postoperative pain and nausea following DCR surgery should not be automatically attributed to wound pain and post-anaesthetic nausea: A AACG needs to be excluded. It may be prudent to assess routinely anterior chamber depth in high risk eyes before DCR surgery. If there is any suspicion of an eye anatomically predisposed to AACG both nursing and medical staff should be made aware of the potential complication. A prophylactic peripheral iridectomy may be indicated.

G A Wilsek
Ocular Plastics Unit, Prince of Wales Hospital, University of New South Wales, Sydney, Australia

M J Vose
Ocular Plastics Unit, Manchester Royal Eye Hospital, Manchester, UK

I C Francis, S Sharma, M T Coroneo
Ocular Plastics Unit, Prince of Wales Hospital, University of New South Wales, Sydney, Australia

Correspondence to: Professor Minas T Coroneo, Ocular Plastics Unit, Eye Clinic, Level 4, Prince of Wales Hospital, High St, Randwick, NSW, 2031, Australia; m.coroneo@unsw.edu.au

Accepted for publication 10 April 2002

References

Presumed hypersensitivity to minocycline and conjunctival infiltration

Minocycline is a widely prescribed systemic antibiotic for acne. Its mechanism of action is complex and not only antimicrobial in nature. Other properties of minocycline include decreased chemotaxis of polymorphonuclear leucocytes, a modification of the complement pathways, an inhibition of the polymorphonuclear leucocyte chemotactic factor, and inhibition of lipase production in Propionibacterium acnes. In ophthalmology, minocycline is used for the treatment of rosacea. Although commonly considered to be a safe drug, there have been an increasing number of reports regarding systemic adverse reactions to minocycline during the past few years. Adverse effects to minocycline range from minor allergic reactions to death. The only ocular side effects reported to date have been cases of presumed minocycline induced scleral pigmentation. We report a case of conjunctival infiltrates, asthma exacerbation, and hypereosinophilia associated with the concurrent use of minocycline.

Case report

A 28 year old woman received oral minocycline 100 mg once daily, for 29 days for the treatment of acne, without any other topical or systemic medication. She had a history of multiple allergies and asthma since early childhood, but no ocular history. During the first days of treatment, she developed asthena, a mild fever of 38°C, and severe asthma. She was hospitalised. Thirty days after the beginning of minocycline treatment, she reported redness and burning of both eyes. Visual acuity was 20/20 in each eye. Several slightly elevated intracutaneous nodules were seen in both eyes at the 12 o’clock position, with injection of the superficial and deep episcleral vessels (Fig 1). The tear film and the corneal epithelium were normal. There was no inflammation of the anterior chamber or of the posterior segment. Laboratory tests showed a severe eosinophilia: 2.12 × 10⁹/l at 15 and 30 days, respectively, after the onset of oral minocycline. Treatment of the patient’s asthma included systemic prednisone initiated at 0.5 mg/kg/day. Cessation of minocycline led to rapid remission of asthma. Despite no topical treatment for her ocular findings, the conjunctival infiltration disappeared, and the ocular symptoms resolved. Laboratory tests showed a rapid decrease of the eosinophil: 1.06 × 10⁹/l and 0.7 × 10⁹/l at 3 and 9 days, respectively, after cessation of minocycline.

A conjunctival biopsy was performed 39 days after the onset of minocycline treatment. Histopathology showed no modifications of the conjunctival epithelium, but oedema of the stroma. Vessels were surrounded by mononuclear lymphocytes and eosinophils. May-Grumwald-Giemsa staining confirmed eosinophilic polymonuclear cells. Such inflammatory aggregates were also seen between vessels but not inside the vessel lumens (Fig 2).

Comment

Reports of adverse effects of minocycline include both hypersensitivity reactions and autoimmune disorders. Hypersensitivity reactions usually occur within a few weeks after the onset of treatment and may lead to exfoliative dermatitis, eosinophilic pneumopathy, pericarditis, lymphadenopathy, pseudoinfectious reactions, and blood eosinophilia (that is >0.6 × 10⁹/l). Autoimmune disorders usually present after exposure to minocycline for 1 year or more and include autoimmune hepatitis, lupus, and vasculitis. Pigmentation of the skin, fingernails, bones, and teeth have also been described in relation to the use of minocycline. Seven cases of scleral pigmentation presumed to have been induced by oral minocycline treatment have been reported.

Exacerbation of asthma and eosinophilia similar to our observation have been previously reported. The definite temporal association with conjunctival infiltration strongly suggested that minocycline therapy was the causative agent in our case. The patient’s clinical findings did not show any abnormality of the superficial corneal epithelium near the limbus or any tear film abnormalities, as observed in a superior limbic keratoconjunctivitis-type reaction. Neither the transient nature of asthma and eosinophilia, nor the biopsy specimen was suggestive of Churg-Strauss disease in our patient. Different ocular manifestations, such as splinter haemorrhages and arterial emboli have been reported in the hypereosinophilic syndrome (eosinophil counts greater than 1.5 × 10⁹/l), linked to chorioretinal thromboembolic disease. No thromboembolic manifestations were observed in the conjunctiva of our patient.

To our knowledge, our observation is the first report of a drug induced eosinophilic conjunctival infiltration.

C Parc, A P Brézin, I Nataf
Department of Ophthalmology, Cochin University Hospital, Paris, France

D Dusser
Department of Pneumology, Cochin University Hospital, Paris, France

L Moachon
Department of Pharmacology, Cochin University Hospital, Paris, France
Importance of molecular testing in dominant optic atrophy

Juvenile onset dominant optic atrophy (DOA) is the most common inherited optic atrophy with a variable prevalence of between 1 in 10,000 (Denmark) and 1 in 50,000. The majority of cases have been shown to have mutations in the OPA1 gene on chromosome 3. Reduced visual acuity of insidious onset, temporal pallor of the optic disc, centrocecal scotoma, and generalised dyschromatopsia are the key clinical features. Recent studies, however, have shown that penetrance within families is much lower than first realised and the assignment of status using clinical criteria alone can result in misdiagnosis. This is well illustrated by the following family.

Fifteen family members were asked about perceived visual difficulties before measurement of visual acuity, colour vision (City University Test), and visual field analysis ( Humphry 24-2). Fundal examination and photography were performed. Blood was taken for screening of the OPA1 coding region using single stranded polymorphism analysis (SSCP) and automated DNA sequencing as previously described.

Seven family members were diagnosed as having optic atrophy from clinical tests alone (Fig 1). Where visual disability was recognised the age of onset ranged from 5.5 to 20 years (Table 1). Eight family members were classified as affected from molecular testing. All individuals exhibited an abnormal banding pattern on SSCP analysis of exon 27 (Fig 2).

Table 1 Data showing the clinical results of visual acuity, colour vision, field analysis, and fundoscopy from selected family members. The colour vision was tested for monocular and binocular tritan (blue-yellow), deutan (green), and protan (red) defects which were scored out of 10 plates

<table>
<thead>
<tr>
<th>Individual</th>
<th>Age (years)</th>
<th>Age of onset (years)</th>
<th>Snellen visual acuity</th>
<th>Centrococcal field defect</th>
<th>City University binocular score</th>
<th>Temporal pallor</th>
</tr>
</thead>
<tbody>
<tr>
<td>I:1*</td>
<td>73</td>
<td>–</td>
<td>6/18 6/18</td>
<td>N N</td>
<td>Tritan Y</td>
<td>Y Y</td>
</tr>
<tr>
<td>I:2*</td>
<td>50</td>
<td>14</td>
<td>6/12 6/12</td>
<td>Y Y</td>
<td>Tritan Y</td>
<td>Y Y</td>
</tr>
<tr>
<td>I:3*</td>
<td>49</td>
<td>20</td>
<td>6/12 6/36</td>
<td>Y Tritan</td>
<td>Y Y</td>
<td></td>
</tr>
<tr>
<td>II:7</td>
<td>48</td>
<td>–</td>
<td>6/6 6/6</td>
<td>N N</td>
<td>Normal</td>
<td>N N</td>
</tr>
<tr>
<td>II:8</td>
<td>50</td>
<td>–</td>
<td>6/6 6/6</td>
<td>N N</td>
<td>Normal</td>
<td>N N</td>
</tr>
<tr>
<td>III:2*</td>
<td>28</td>
<td>–</td>
<td>6/18 6/18</td>
<td>Y Y</td>
<td>Generalised Y</td>
<td>Y Y</td>
</tr>
<tr>
<td>III:3*</td>
<td>23</td>
<td>7</td>
<td>6/36 6/18</td>
<td>Y Y</td>
<td>Generalised Y</td>
<td>Y Y</td>
</tr>
<tr>
<td>III:4*</td>
<td>19</td>
<td>12</td>
<td>6/18 6/12</td>
<td>Y Y</td>
<td>Normal</td>
<td>N N</td>
</tr>
<tr>
<td>III:7*</td>
<td>6</td>
<td>5.5</td>
<td>6/12 6/9</td>
<td>N N</td>
<td>Generalised Y</td>
<td>Y Y</td>
</tr>
</tbody>
</table>

Y = Yes; N = No. *Classified as affected from clinical tests alone.

References
C Toomes, N J Marchbank, C F Inglehearn
Molecular Medicine Unit, University of Leeds, Leeds LS9 7TF, UK

N Foulds
St George’s Hospital and School of Medicine, London SW17 4QL, UK

A Moosavi, M Teimory
West Sussex Eye Unit, Worthing and St Richard’s Hospital, West Sussex, BN11 2DF, UK

Correspondence to: Dr Patel; dinish1975@yahoo.com

Accepted for publication 1 May 2002

References

Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinemia

A 64 year old man presented to the corneal service complaining of glare at night which had worsened over a 12 month period. He was found to have a pancorneal epithelial crystalline keratopathy with normal Snellen acuity (6/5 both eyes) and an otherwise unremarkable ocular examination (anterior chamber, lens, vitreous, and fundus). The crystalline keratopathy was described as arising from limbus to limbus and consisted of a homogeneous spread of tiny yellow crystals located in the epithelium and to a lesser extent the anterior corneal stroma. Two months later, following investigation for breathlessness he was diagnosed as suffering from multiple myeloma. Investigations revealed a raised plasma viscosity (3.28 s), an IgG paraprotein (55.9 g/l), free immunoglobulin light chains in the urine (0.49 g/24 hours), a hypercellular bone marrow aspirate (70%–80% plasma cells), and a single lytic bone lesion in the left iliac crest. He was entered into the MRC Myeloma Trial (Myeloma VII) and was randomised to receive ABCM (adriamycin, BCNU, cyclophosphamide, melphalan). However, his renal function rapidly deteriorated (creatinine 714 μmol/l) requiring plasma exchange. Seven courses of ABCM were completed before the myeloma reached plateau phase (paraprotein 23.0 g/l) and the thalidomide reduced to 50 mg twice weekly. Within 7 months of starting the thalidomide, the paraprotein had worsened over a 12 month period. He was re-introduced when the disease was progressing (paraprotein 52.8 g/l) and no longer responding to treatment. Initially he was started upon 50 mg daily; however, a peripheral neuropathy developed when the dose was increased to 100 mg alternate days and latterly to 50 mg twice weekly. Within 7 months of starting the thalidomide, the paraprotein had completely disappeared and the crystalline keratopathy had resolved (Fig 1C, D). Visual acuity at this time was 6/9 right eye and 6/18 left eye, due now in large part to the presence of early posterior subcapsular lens opacity.

Comment

Corneal crystalline deposits may occur in cystinosis, multiple myeloma, and other monoclonal gammapathies, infective crystalline keratopathy, Schzyder’s central crystalline dystrophy, Bietti’s marginal crystalline dystrophy, gout, chronic renal disease, lipid keratopathy, and chrysiasis.1

Crystalline keratopathy occurs only rarely in association with multiple myeloma and monoclonal gammapathies.2,3 With the exception of Waldenstrom’s macroglobulinaemia, the crystals are composed of IgG light chains (usually κ but occasionally λ). The crystals may be deposited in the epithelium, as in the case we present, where they have been reported to lie both between and within the epithelial cells4,5 and also within the cells of the cornal stroma,6 conjunctiva, and lens.7,8,9,10

It is not known why crystallisation occurs so infrequently in these conditions or why clinical appearances are so diverse, but factors including the structure, chemical properties and concentration of the paraprotein or its metabolites, the local tissue environment and the epithelial cells are likely determinants. The effect of concentration cannot be disputed as the crystals tend to disappear as the paraprotein concentrations fall; however, the rarity of these corneal crystalline depositions suggests that the chemical and tertiary structures of the proteins or their metabolites is critically important.

Although it is reported that myeloma associated crystalline keratopathy can disappear in response to chemotherapy11 and plasma exchange there are no previous reports of resolution following the use of thalidomide in refractory disease. The mechanisms of action of thalidomide are complex and poorly defined but include immunomodulatory and anti-inflammatory effects, the modulation of TNFα, T cell proliferation, increased levels of IFN-γ and modulation of WBC migration and chemotaxis. The drug also has important anti-angiogenic effects which may be related to modulation of TNFα or a direct inhibitory effect upon angioproliferation. Thalidomide is also sedative and hypnotic and its use for these latter effects gained infamy in the 1960s. Used as single treatment for refractory or relapsed myeloma thalidomide represents one of the most significant advances in myeloma management in the past 20 years. Around a third to two thirds of patients are said to respond to thalidomide, typically within 2 months. The response is marked by a significant (25% to a least 90%) reduction in paraprotein and Bence-Jones proteins with some.

Figure 1 Slit lamp photographs of the left cornea. (A) Before thalidomide, low power. (B) Before thalidomide, high power. (C) After thalidomide, low power (pupil dilated). (D) After thalidomide, high power (pupil dilated).
like our patient, achieving complete remis-
sion. Although the anti-angiogenic effects of
thalidomide are generally considered a key
factor in the efficacy of the drug in multiple
myeloma, the poor response of extramedu-
lular plasmacytomas and the lack of correla-
tion between bone marrow microvascular
density and clinical response suggest that
other actions of the drug may also be
important.1

In summary, we report a case of a refractory
multiple myeloma with associated corneal
abnormality and clinical genetic
diagnosis among the most common of the micro-
deletion syndromes and is characterised by
cardiac malformations (particularly outflow
tract), craniofacial features, cleft palate, thymic
hypoplasia, and hypoparathyroidism. The
severity of the condition can be very vari-
able and is now recognised as the basis of sev-
eral independently described syndromes: Di-
George syndrome (DGS), conotruncal face
anomaly syndrome, and velo-cardio-facial
syndrome (Shprintzen syndrome).3 The “velo” in
VCFS refers to the palatal abnormalities such as
cleft palate that are sometimes present. The
characteristic facial appearance of del(22)(q11.22) is a prominent nose, broad
nasal root, narrow palpebral fissures, and
retrognathia.2 Recognised ocular features in-
clude retinal vascular tortuosity, small optic
nerves, and narrow palpebral fissures.4 An iris
coloboma has been described in one case of
VCFS and coloboma was listed as a rare
feature in a series of cases of DGS.5

Case report
As part of a population based study of children with congenital anophthalmia, cli-
nical microphthalmia, or iris coloboma (with or
without fundus coloboma), we identified a
teenage girl with bilateral iris coloboma, right
fundus coloboma, left cataract, and clinical
microphthalmia (Fig 1). On further examina-
tion she was found to have upslanting palpe-
bral fissures, prominent nose, small mouth,
dental crowding, unilateral deafness, arachno-
dactyly, second and third toe syndactyly (Fig
2), a ventriculocoele defect (VSD) requiring
surgical correction, and developmental delay.
Both parents had no eye abnormality. A clini-
cal diagnosis of VCFS was made and micro-
satellite analysis of this girl's DNA along with
confirmation that the velo-cardio-facial
syndrome is associated with haploinsufficiency
of genes at chromosome 22q11.11 Am. J Med

Ocular findings in the velo-cardio-facial

Beemer FA, de Nef JEM, Delleman JW, et al.
Additional eye findings in a girl with the

Berends MJW, Dirksen A, Koomen GM, de
Nef JJEM, Delleman JW, et al. Additional eye
findings in a girl with the velo-cardio-facial

Confirmation that the velo-cardio-facial
syndrome is associated with haploinsufficiency
of genes at chromosome 22q11.11 Am. J Med

Ocular findings in the velo-cardio-facial

Beemer FA, de Nef JEM, Delleman JW, et al.
Additional eye findings in a girl with the

Berends MJW, Dirksen A, Koomen GM, de
Nef JJEM, Delleman JW, et al. Additional eye
findings in a girl with the velo-cardio-facial

References
1 Shapiro SK. An update on chromosome
deletion and microdeletion syndromes. Curr
Confirmation that the velo-cardio-facial
syndrome is associated with haploinsufficiency
of genes at chromosome 22q11.11 Am. J Med
Genet 1993;45:308–12.
Ocular findings in the velo-cardio-facial
5 Beemer FA, de Nef JEM, Delleman JW, et al.
Additional eye findings in a girl with the
6 Berends MJW, Dirksen A, Koomen GM, de
Nef JJEM, Delleman JW, et al. Additional eye
findings in a girl with the velo-cardio-facial

Amniotic membrane
transplantation for necrotising
conjunctival ulceration following
subconjunctival atropine
injection
Conjunctival necrosis has been previously
reported after subconjunctival injection of
several antimicrobial agents and
corticosteroids.10 Atropine is used widely as a
form of eyedrops for mydriasis, cyclopia,
and pain and inflammation control. We

Figure 1 Bilateral iris coloboma with
clinical microphthalmos in a girl with
velo-cardio-facial syndrome. Note the
upslanting and narrow palpebral fissures,
wide nasal root and bridge, with prominent
nose, and small mouth.

Figure 2 Second and third toe syndactyly
in a girl with velo-cardio-facial syndrome
and del(22)(q11.22).

Iris coloboma and a
microdeletion of chromosome
22: del(22)(q11.22)
A 22q11 microdeletion is described in a girl
with ocular coloboma associated with velo-
cardio-facial syndrome (VCFS).

Microdeletion syndromes are a heterogene-
ous group of disorders caused by deletion of
specific regions of chromosomal DNA that are
not visible using standard chromosome
analysis.1 Microscopic chromosome deletions
are being recognised increasingly as a cause of
genital abnormalities and clinical genetic
syndromes. Laboratory confirmation of these
conditions requires specialist molecular test-
that must be requested on the basis of

Group.bmj.com on September 7, 2017 - Published by http://bjo.bmj.com/ Downloaded from

For personal use only. This PDF file is not to be distribu-
ted in any form.

www.bjophthalmol.com
describe a patient who developed severe conjunctival necrosis associated with scleral melting after subconjunctival atropine injection and which was treated by amniotic membrane transplantation.

Case report
A 30 year old male patient visited our clinic because of severe pain and redness in his left eye for a day. He had recently been diagnosed with uveitis associated with circular posterior synechiae in his left eye, and which was managed by his previous physician with a subconjunctival injection of 0.4 ml of atropine (10 mg/ml, atropine sulphate, powder dissolved in saline, Mallinckrodt, St Louis, MO, USA) to lyse the posterior synechiae. Upon consultation at our institute, he was found to have marked conjunctival injection and chemosis all around the limbus. Three days after the atropine injection, large areas of necrosis developed around the whole limbus (Fig 1). White necrotic materials were noted on the underlying sclera and episclera. The underlying sclera in the inferotemporal bulbar conjunctiva showed a considerable area of melting (2 × 3 mm).

We decided to manage the defect by amniotic membrane transplantation to the sclera because of the large extent of the defect and the scleral involvement. Debridement of the necrotic conjunctiva and episclera was done and the defect was covered with an amniotic membrane graft, which was obtained from women undergoing elective caesarean section and preserved at −70°C. The amniotic membrane was placed basement membrane side up and the excess membrane was trimmed. The edges of them were sutured to the borders of the conjunctiva and the limbus with 10-0 nylon. Topical 0.3% ofloxacin and 1% prednisolone acetate were prescribed every 2 hours postoperatively.

For the next week, the patient improved steadily, having less pain and redness. After a month, the necrotised defect was re-epithelialised completely without inflammation, scar, or symblepharon formation (Fig 2). The eyedrops were tapered to four times daily for 2 weeks, twice daily for more 2 weeks, and then stopped.

References

Traumatic enucleation with chiasmal damage: magnetic resonance image findings and response to steroids
Gouging has been reported throughout history and this case demonstrates it is still encountered in modern times. Its impact on visual function extends beyond the loss of an eye because of concomitant psychological morbidity.

Case report
We present a case report of a patient who suffered a traumatic enucleation. Our patient is a 24 year old security manager who, while trying to prevent youths from harassing

Figure 1 Photographic view taken soon after assault showing the right gouged eye and avulsed optic nerve.

Figure 2 [A] Slit lamp photograph of left eye 1 month after treatment. The conjunctiva is completely healed. (B) The necrotised defect in the superior conjunctiva was re-epithelialised without any scar formation or symblepharon.
passengers on a bus, was assaulted by one of them. The attacker grabbed the patient from behind and attempted to insert his index fingers into each orbit, successfully on the right and the right eye was gouged out (Fig 1). He also sustained a minor head injury following some blows to the head but was not knocked out.

Following examination the only remaining attachments to the globe were the lateral rectus and inferior oblique. His optic nerve was completely avulsed. Examination of his left eye revealed a temporal hemianopia. His vision was 6/6. He was admitted and taken to theatre for a complete enucleation.

He had a Goldmann field performed which confirmed a temporal hemianopia. An magnetic resonance imaging (MRI) scan was carried out which showed swelling of the left side of the chiasm (Fig 2) He had a 3 day course of intravenous methylprednisolone after MRI findings. There was an interval of 12 days between the day of injury and commencing methylprednisolone.

His visual field test done at the end of the 3 day course of methylprednisolone showed a marked improvement in the inferotemporal field which may be attributed to the steroids.

B Parmar, B Edmunds, G Plant
Eye Department, St Thomas’s Hospital, Lambeth Palace Road, London SE1 7NH, UK
Correspondence to: B Parmar; parmabina@hotmail.com
Accepted for publication 13 May 2002

References

Cyclodiode laser therapy to control intraocular pressure during pregnancy

Controlling intraocular pressure (IOP) during pregnancy can be problematic because currently available topical ocular hypotensive agents are contraindicated during pregnancy. We report the case of a patient with aphakic glaucoma controlled with topical agents, for whom we performed cyclodiode laser therapy, since she wanted to become pregnant. The use of cyclodiode laser therapy for this indication has not been described previously.

Case report
A 30 year old woman was referred to our specialist glaucoma clinic with a diagnosis of aphakic glaucoma in her right eye. She had a past ophthalmologic history of chronic uveitis secondary to juvenile chronic arthritis, complications right cataract surgery and subsequent aphakic glaucoma.

At the time of referral her visual acuities were 6/36 in her right aphakeye and 6/5 in the left eye. She had an IOP of 19 mm Hg in her right eye and significant disc cupping (cup/disc ratio 0.85). Her right IOP was controlled with dorzolamide eye drops 2%, carteolol eye drops 2%, both twice a day, and latanaprost eye drops 0.005% at night. Our patient wanted to become pregnant but was justifiably concerned that the topical medication she was using might affect her pregnancy. It was decided that we would perform cyclodiode laser therapy on her right eye, under peribulbar anaesthesia, and stop her topical antiglaucomatous therapy. The first session of cyclodiode (1500 µW × 1500 µs × 40 shots over 360°) with 5 and 9 o’clock sparing was unsuccessful and 6 weeks later her IOP was 33 mm Hg on no ocular hypotensive therapy. The second session of cyclodiode therapy (2000 µW × 2000 µs × 40 shots) was partially successful, the IOP being 22 mm Hg 6 weeks later, although this had risen to 28 mm Hg by 4 months. By this time our patient had become pregnant and it was felt that the IOP was still too high. A third attempt at lowering IOP by cyclodiode (2000 µW × 2000 µs × 40 shots over 360°) was made, following which the IOP was persistently well controlled at 12–14 mm Hg.

Comment
The use of cyclodiode laser therapy to control IOP in women before and during pregnancy has not been described. It seems a rational choice in treating these patients since the use of topical antiglaucomatous therapy is either contraindicated or cautioned in pregnancy. β Blockers, sympathomimetics, carbonic anhydrase inhibitors, parasympathomimetics, apraclonidine, and prostaglandin analogues have all been shown to have adverse effects in animal fetal models. Understandably, there have been no equivalent studies in the human fetus and resulting teratogenesis in laboratory animals cannot be extrapolated to humans. However, some specific examples of adverse effects related to specific topical medicinal preparations have been quoted in the literature. Topical timolol has been shown to cause fetal cardiac arrhythmia and bradycardia. There has been one reported case that correlates the use of acetazolamide in early pregnancy with sacrococcygeal teratoma in the neonate. Prostaglandins are involved in the physiology of pregnancy and thus the use of latanaprost is not advised during pregnancy.

Figure 2 Arrow A shows high signal left hemichiasm and arrow B shows normal right hemichiasm.

Figure 3 A left temporal hemianopia after injury (left) and the repeat Goldmann perimetry following pulsed methylprednisolone (right).
Pregnancy is usually a period of lower IOP, and less therapy may be required than before gestation, although that was not the case with our patient. It could be argued that optic nerve damage over a 9-month period would be minimal such that a mildly raised IOP could be tolerated for the length of pregnancy. However, when glaucomatous damage is severe, it is generally accepted that a low target IOP should be attained.

There is a paucity of literature describing the use of local anaesthetics for ophthalmic procedures during pregnancy. However, in a large multicentre retrospective study, exposure to local anaesthetic during early pregnancy was not associated with any increased risk of congenital malformation. Our patient could have been offered augmented filtration or tube implantation surgery but cycloplegia was felt to be less invasive and, ideally, exposure to antimetabolites should be avoided in pregnancy. Cycloplegia is a safe and effective treatment to control IOP before and during pregnancy. The risk of topical medication to the fetus is eliminated and more complex surgical intervention with general anaesthesia is avoided.

W Wertheim, D C Broadway
Eye Department, Norfolk and Norwich University Hospital, Norwich NR4 7UZ, UK
Correspondence to: Dr Wertheim; dwwerthe@hotmail.com
Accepted for publication 20 May 2002

References

MAILBOX

Pupillary autonomic denervation and diabetes mellitus

Recently, Cahill et al published a paper on pupillary autonomic denervation in diabetic patients. In our own recent study we can confirm the presence of a small dark adapted pupil size (DAP) before cardiovascular autonomic dysfunction is detected in patients with type I diabetes mellitus. We believe that this is an important observation, since autonomic alterations may cause an increase in mortality as repeatedly evidenced for cardiac autonomic neuropathy (CANN). In particular, we found a significantly reduced DAP in patients with normal ranges in high frequency waves of heart spectral analysis as a marker for cardiac parasympathetic nerve lesions and in variation coefficient of heart rate variability. We could also show significantly reduced pupillary responses to cocaine 4% eye drops in patients with CAN as a test for sympathetic nerve alterations. The DAP of patients with CAN did not yield significant differences from the age matched controls. Patients without any systemic diabetic autonomic neuropathy had a significantly reduced DAP and in variation coefficient defined as CAN, peripheral sensorimotor neuropathy, retinopathy, and nephropathy had no significant differences in their DAP compared to the probands.

Thus, it is of interest if patients in this study with CAN also significantly differ in their pupillary responses to cocaine, and if patients without CAN possibly have other diabetic long term complications or increased glycosylated haemoglobin levels, which may correlate with the small DAP.

Nevertheless, this study by Cahill et al clearly indicates that screening for pupillary dysfunction is mandatory as early as possible to prevent the sequelae of other autonomic neuropathic disorders.

D Pittasch, R Lobmann, H Lehnert
Department of Endocrinology and Metabolism, Magdeburg University Medical School, Germany
W Behrens-Baumann
Department of Ophthalmology
Correspondence to: H Lehnert; hendrik.lehnert@medizin.uni-magdeburg.de

References

Choroidal ischaemic infarction following ocular contusion with small framed spectacles: Hutchinson-Siegrist-Neubauer-syndrome

We read with interest the article by Clarke et al. The authors describe their findings in a 79 year old aphakic woman with a so called non-penetrating injury caused by compression of the globe. "We read with interest the article by Clarke et al with regard to the multiple mechanism of choroidal ischaemia and as an interesting finding that showed a small dark adapted pupil size (DAP) before cardiovascular autonomic dysfunction is detected in patients with type I diabetes mellitus."

We found Hutchinson-Siegrist-Neubauer syndrome in 1% of all contusions of the Erlangen Ocular Contusion Registry.

Our theory is supported with the recommendation of Vinger, who discussed the need for appropriate protective eyewear for all patients who had undergone intraocular surgery. Currently, high risk patients—that is, after ICCE surgery.

A Viestenz, M Küche
Department of Ophthalmology, University Erlangen-Nürnberg, Schwabachanlage 6, D91054 Erlangen, Germany
Correspondence to: Arne Viestenz, MD, Department of Ophthalmology, University Erlangen-Nürnberg, Schwabachanlage 6, D91054 Erlangen, Germany; Arne.Viestenz@online.de

References

Anti-Acanthamoeba efficacy in contact lens disinfecting systems

Hiti et al produced an interesting study investigating the susceptibility of three strains of Acanthamoeba to a PHMB (polyhexamethylene biguanide) based multipurpose solution (MPS), a one step peroxide system (3%, H2O2), and a two step peroxide system (0.6% H2O2). However, no comment was made regarding
Million CFU/mL. This is higher than that found in the majority of soft lens MPS, which contain 0.0001% PHMB. As the minimum peroxide activity concentration (MTAC) of PHMB is 1 µg/mL and the minimum cystidial concentration (MCC) is 3 µg/mL, the solution has performed as expected against the clinical isolates. Also, a recent study by our group testing the efficacy of a variety of MPS for soft lenses, including one containing 0.0005% PHMB, found this concentration to be cysticidal after the manufacturer’s recommended disinfection time of 4 hours. A test solution with a 1:1 dilution of a 3% hydrogen peroxide lens solution (0.6% or 6000 µM) was as expected. In addition, a recent cohort study of CL wearers in Hong Kong has shown that lens storage cases were more likely to cause keratitis in humans. This isolate belongs to A. castellanii, which has not previously been reported as causing keratitis.

The results for the three solutions when compared against clinical isolates of A. castellanii were as expected. The authors concluded by recommending the two step peroxide system, by concluding that a 1:2 dilution of a 3% hydrogen peroxide contact lens disinfection solution (0.6% H2O2) for overnight contact lens storage is rapidly neutralised. If a 1:1 dilution (3000 µg/mL) of this solution was tested as expected by Zanetti et al., demonstrated that a 1:2 dilution of a 3% hydrogel based solution killed out of 6 of 10 clinical strains after a 9 hour exposure, but not a 1:1 dilution (0.3% or 3000 µg/mL) had lost its cystidical effect.

The majority of two step peroxide systems currently available contain 3% hydrogen peroxide. The two-step peroxide system (0.6% H2O2) for overnight disinfection is rapidly neutralised. Therefore, again, the results for the one step peroxide system were as expected. In addition, a recent cohort study of CL wearers in Hong Kong has shown that lens storage cases were more likely to cause keratitis in humans. This isolate belongs to A. castellanii, which has not previously been reported as causing keratitis.
for any queries or worries relating to the problems retinitis pigmentosa can bring. This service is especially valuable for those recently diagnosed with retinitis pigmentosa, and all calls are taken in the strictest confidence. Many people with retinitis pigmentosa have found the Society helpful, providing encouragement, and support through the Helpline, the welfare network and the BRPS branches throughout the UK. (tel: +44 (0)1280 821 334; email: lynda@brps.demon.co.uk; website: www.brps.demon.co.uk)

Introductory Course in Osteo-odonto-keratoprosthesis (OOKP)
The University of Brighton Postgraduate Medical School is holding an introductory course in osteo-odonto-keratoprosthesis (OOKP) 20–21 November 2002 in the New Seminar Room, Sussex House, Brighton & Sussex University Hospitals Trust in Brighton. The course will comprise of a variety of lectures with live surgery, two way audio and video links (Stage 1 and Stage 2 OOKP surgery), and examination of patients. Further details: Mrs Erica Strange, University of Brighton, Postgraduate Medical School, Falmer Campus, Brighton, East Sussex BN1 9PH, UK (tel: +44 (0)1273 644 005; fax: +44 (0)1273 644 002; email: e.strange@brighton.ac.uk).

23rd Annual Conference and Dinner Glaucoma Society (UK & EIRE)
The 23rd Annual Conference and Dinner of the Glaucoma Society will be held on Thursday 21 November 2002, 8.30am to 5.00pm at the Central Conference Centre, London. The Annual Dinner is from 6.30pm to 10.00pm at The Royal College of Surgeons, London. Conference charges: £60 members; £80 non-members. Price entitles delegates to refreshments, lunch, abstract book, programme, and annual dinner. (Maximum number of places 290—apply now to secure your place). Further details: Janet Flowers, Administrator, 29 Quarry Hill, Grays, Essex, RM17 5BT, UK (tel/fax: 01375 383172; email: glauhoc@ukeire.freeserve.co.uk).

Retinal Detachment Course with international faculty and case presentations preceding Vitrektomie-Kurs—Wetlab
The Retinal Detachment Course with international faculty and case presentations and Vitrektomie-Kurs—Wetlab will be held 13 February 2003 (in English) and 14–15 February 2003 (in German) respectively, at Verwaltungsgebäude der KA Rudolfstiftung, 1030 Vienna, Boehringer Gasse 8a, Austria. Further details and registration: Firma Askin & Co, Albert-Schweritzer-Gasse 6, A-1140 Vienna, Austria (tel: +43 (1) 979 88 44; fax: +43 (1) 979 88 46).

Detachment Course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding Retina Meeting
The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations and the Retina Meeting will be held 14–15 March 2003 and 16 March 2003 respectively, in Mexico City, Mexico. Further details: Scientific programme: Prof Ingrid Kreissig, University of Tuebingen, Schleichstr. 12, Breuningerbaur, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid.kreissig@med.uni-tuebingen.de).

Local organisation: Prof. Quiroz-Mercado, Prof. Munoz, and Prof Gonzalez “Hospital Luis Sanchex Bulnes”, Asociacion para Evitar la Ceguera en Mexico Vicente Garcia Torres #46, Coyosacan, Mexico DF 04330 (fax: +5255 5659 5928; email: retinamex@yahoo.com).

16th Annual Meeting of German Ophthalmic Surgeons
The 16th Annual Meeting of German Ophthalmic Surgeons will be held 8–11 May 2003 in Nürnberg, Germany. Messezentrum. Organised by the Professional Association of German Ophthalmologists Ophthalmic Surgery Group the conference will cover cataract surgery, refractive surgery, glaucoma surgery, vitreoretinal surgery, corneal surgery, eye surgery in developing countries, and orbita, lacrimal and lid surgery. Further details: MCN Medizinische Congress organisation Nürnberg AG, Zerzabelshofstr 29, 90478 Nürnberg, Germany (tel: +49 911 3931621; fax: +49 911 3931620; email: doc@mcnag.info; website: www.doc-nuernberg.de).

Detachment Course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding the Annual Meeting of Iranian Society of Ophthalmology
The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding Annual Meeting of Iranian Society of Ophthalmology will be held on 29–30 November 2003 and 1–4 December 2003 respectively, at the Razi Conference Center, Hemmat Hyw, Tehran, Iran. Further details: Scientific programme: Prof Ingrid Kreissig, University of Tuebingen, Schleichstr. 12, Breuningerbaur, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid.kreissig@med.uni-tuebingen.de).

Local organisation: Dr Arman Masheyekhi, Dr Siamak Moradian, Dept of Ophthalmology, Labanlinejad Medical Center, Pasdaran Ave, Boostan 9, Tehran, 16666, Iran (fax: +98 21 254 9039; email: labbali@hotmail.com).
Amniotic membrane transplantation for necrotising conjunctival ulceration following subconjunctival atropine injection
K Y Seo, C Y Kim, J H Lee, J B Lee and E K Kim

*Br J Ophthalmol* 2002 86: 1316-1317
doi: 10.1136/bjo.86.11.1316-a

Updated information and services can be found at:
http://bjo.bmj.com/content/86/11/1316.2

These include:

References
This article cites 9 articles, 1 of which you can access for free at:
http://bjo.bmj.com/content/86/11/1316.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/